A new COVID-19 vaccine could hit the markets

May 17, 2021

The French Sanofi and Britain’s GlaxoSmithKline announced the upcoming Phase III of their experimental vaccine

According to Sanofi, the vaccine showed a robust immune response in early-stage clinical trials results, which allows them to move to a late-stage study. A global Phase III could start in the coming weeks, involving over 35,000 adults. The companies hope for the vaccine to be approved by the fourth quarter, later than initially planned.

The announcement comes after, in December, Sanofi and GSK had to restart the trial after the vaccine showed a low immune response in older adults as a result of a weak antigen formulation.

Su-Peing Ng, Sanofi’s global head of medical for vaccines, revealed that during Phase III, the vaccine would also be tested against various strains of COVID-19, including the lineage detected in South Africa. Moreover, the shot could be used as a potential booster, no matter of what vaccine someone might have received beforehand.

So far, Sanofi has purchasing agreements with the US, EU, Britain, Canada, and with COVAX – a World Health Organization-backed facility.

At the moment of writing, Sanofi stock price is trading 0.91% higher, while GSK is up 0.83%.

Source: reuters.com

This information prepared by ClickTrades.com is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.

This information is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation or the particular needs of any recipient.

You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.

This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent.

Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of ClickTrades.com.